What is VANI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VANI?

P/E (TTM) is n/a and 52-week range is $0.92 to $1.92 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VANI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VANI?

The company profile lists revenue (TTM) near $3M, net income (TTM) near $-3.36B, EPS (TTM) near $-0.36 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vivani Medical Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Alameda, California, US, 86.2M shares outstanding, ISIN US92854B1098 when available from company profile and filing metadata.

Vivani Medical Inc

$VANI

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$1.25

+1.63%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Employees

Website

vivani.com/

IPO

2014-12-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)